A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain

Journal of Proteome Research

Volumn 14, Issue 1, 2015, Pages 411-421

  Wesseling, Hendrik ^a   Rahmoune, Hassan ^a   Tricklebank, Mark ^b   Guest, Paul C ^a   Bahn, Sabine ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

animal model; ketamine; major depressive disorder; MSstats; multiplex immunoassay; NMDA receptor antagonist; pharmacological treatment; rat; schizophrenia; SRM

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA INTERNEXIN; ASPARTATE AMINOTRANSFERASE ISOENZYME 2; CALCINEURIN; CATECHOL METHYLTRANSFERASE; FIBROBLAST GROWTH FACTOR 9; GLUTAMATE RECEPTOR 2; INTERLEUKIN 4; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROCHONDRIN; PHOSPHOPROTEIN PHOSPHATASE; PROHIBITIN; PROTEIN KINASE; PROTEIN KINASE C BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SYNAPSIN I; SYNDAPIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATASE;

ADULT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOASSAY; INFLAMMATION; MAJOR DEPRESSION; MASS SPECTROMETRY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RAT; SCHIZOPHRENIA; SYNAPSE VESICLE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES;

ANIMALIA; MAMMALIA; RATTUS; RODENTIA;

ANIMALS; BIOMARKERS; BRAIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOASSAY; KETAMINE; MASS SPECTROMETRY; PHOSPHORIC MONOESTER HYDROLASES; PRINCIPAL COMPONENT ANALYSIS; PROTEIN KINASES; PROTEOMICS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84920261147     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr5009493     Document Type: Article

References (99)

1. Zarate, C. A., Jr.; Singh, J. B.; Carlson, P. J.; Brutsche, N. E.; Ameli, R.; Luckenbaugh, D. A.; Charney, D. S.; Manji, H. K. A randomized trial of an N -methyl- d -aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 2006, 63 (8) 856-864
2. Zarate, C. A., Jr.; Singh, J. B.; Quiroz, J. A.; De Jesus, G.; Denicoff, K. K.; Luckenbaugh, D. A.; Manji, H. K.; Charney, D. S. A double-blind, placebo-controlled study of memantine in the treatment of major depression Am. J. Psychiatry 2006, 163 (1) 153-155
3. Kapur, S.; Seeman, P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia Mol. Psychiatry 2002, 7 (8) 837-844
4. Horiguchi, M.; Hannaway, K. E.; Adelekun, A. E.; Huang, M.; Jayathilake, K.; Meltzer, H. Y. D-1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats Behav. Brain Res. 2013, 238, 36-43
5. Becker, A.; Peters, B.; Schroeder, H.; Mann, T.; Huether, G.; Grecksch, G. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27 (4) 687-700
6. Gastambide, F.; Mitchell, S. N.; Robbins, T. W.; Tricklebank, M. D.; Gilmour, G. Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat Eur. Neuropsychopharmacol. 2013, 23 (11) 1414-1422
7. Lipska, B. K.; Weinberger, D. R. To model a psychiatric disorder in animals: schizophrenia as a reality test Neuropsychopharmacology 2000, 23 (3) 223-239
8. Bubenikova-Valesova, V.; Horacek, J.; Vrajova, M.; Hoschl, C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors Neurosci. Biobehav. Rev. 2008, 32 (5) 1014-1023
9. Zugno, A. I.; de Miranda, I. M.; Budni, J.; Volpato, A. M.; Luca, R. D.; Deroza, P. F.; de Oliveira, M. B.; Heylmann, A. S.; Silveira, F. D.; Wessler, P.; Mastella, G. A.; Cipriano, A. L.; Quevedo, J. Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia Neuroscience 2013, 248, 252-260
10. Li, N. X.; Lee, B.; Liu, R. J.; Banasr, M.; Dwyer, J. M.; Iwata, M.; Li, X. Y.; Aghajanian, G.; Duman, R. S. mTOR-Dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 2010, 329 (5994) 959-964
11. Garcia, L. S.; Comim, C. M.; Valvassori, S. S.; Reus, G. Z.; Barbosa, L. M.; Andreazza, A. C.; Stertz, L.; Fries, G. R.; Gavioli, E. C.; Kapczinski, F.; Quevedo, J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32 (1) 140-144
12. Koike, H.; Iijima, M.; Chaki, S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behav. Brain Res. 2011, 224 (1) 107-111
13. Garcia, L. S.; Comim, C. M.; Valvassori, S. S.; Reus, G. Z.; Stertz, L.; Kapczinski, F.; Gavioli, E. C.; Quevedo, J. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33 (3) 450-455
14. Autry, A. E.; Adachi, M.; Nosyreva, E.; Na, E. S.; Los, M. F.; Cheng, P. F.; Kavalali, E. T.; Monteggia, L. M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 2011, 475 (7354) 91-U109
15. Li, N. X.; Liu, R. J.; Dwyer, J. M.; Banasr, M.; Lee, B.; Son, H.; Li, X. Y.; Aghajanian, G.; Duman, R. S. Glutamate N -methyl- d -aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol. Psychiatry 2011, 69 (8) 754-761
16. Chatterjee, M.; Verma, R.; Ganguly, S.; Palit, G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice Neuropharmacology 2012, 63 (6) 1161-1171
17. De Kock, M.; Loix, S.; Lavand'homme, P. Ketamine and peripheral inflammation CNS Neurosci. Ther. 2013, 19 (6) 403-410
18. Hurley, L. L.; Tizabi, Y. Neuroinflammation, neurodegeneration, and depression Neurotoxic. Res. 2013, 23 (2) 131-144
19. Park, S. W.; Lee, J. G.; Seo, M. K.; Lee, C. H.; Cho, H. Y.; Lee, B. J.; Seol, W.; Kim, Y. H. Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons Int. J. Neuropsychopharmacol. 2014, 17, 1-16
20. Huang, L.; Liu, Y.; Jin, W.; Ji, X.; Dong, Z. Ketamine potentiates hippocampal neurodegeneration and persistent learning and memory impairment through the PKCgamma-ERK signaling pathway in the developing brain Brain Res. 2012, 1476, 164-171
21. Reus, G. Z.; Vieira, F. G.; Abelaira, H. M.; Michels, M.; Tomaz, D. B.; Dos Santos, M. A.; Carlessi, A. S.; Neotti, M. V.; Matias, B. I.; Luz, J. R.; Dal-Pizzol, F.; Quevedo, J. MAPK signaling correlates with the antidepressant effects of ketamine J. Psychiatr. Res. 2014, 55, 15-21
22. Kavalaii, E. T.; Monteggia, L. M. Synaptic mechanisms underlying rapid antidepressant action of ketamine Am. J. Psychiatry 2012, 169 (11) 1150-1156
23. Naughton, M.; Clarke, G.; O'Leary, O. F.; Cryan, J. F.; Dinan, T. G. A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action J. Affective Disord. 2014, 156, 24-35
24. Rosso, S. B.; Sussman, D.; Wynshaw-Boris, A.; Salinas, P. C. WNT signaling through dishevelled, Rac and JNK regulates dendritic development Nat. Neurosci. 2005, 8 (1) 34-42
25. Bai, X. W.; Yan, Y. S.; Canfield, S.; Muravyeva, M. Y.; Kikuchi, C.; Zaja, I.; Corbett, J. A.; Bosnjak, Z. J. Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway Anesth. Analg. 2013, 116 (4) 869-880
26. de Oliveira, L.; Spiazzi, C. M. D.; Bortolin, T.; Canever, L.; Petronilho, F.; Mina, F. G.; Dal-Pizzol, F.; Quevedo, J.; Zugno, A. I. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33 (6) 1003-1008
27. Zugno, A. I.; Chipindo, H. L.; Volpato, A. M.; Budni, J.; Steckert, A. V.; de Oliveira, M. B.; Heylmann, A. S.; Silveira, F. D.; Mastella, G. A.; Maravai, S. G.; Wessler, P. G.; Binatti, A. R.; Panizzutti, B.; Schuck, P. F.; Quevedo, J.; Gama, C. S. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia Neuroscience 2014, 259, 223-231
28. Rezin, G. T.; Goncalves, C. L.; Daufenbach, J. F.; Fraga, D. B.; Santos, P. M.; Ferreira, G. K.; Hermani, F. V.; Comim, C. M.; Quevedo, J.; Streck, E. L. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress Brain Res. Bull. 2009, 79 (6) 418-421
29. Hroudova, J.; Fisar, Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants Toxicol. Lett. 2012, 213 (3) 345-352
30. Littlewood, C. L.; Jones, N.; O'Neill, M. J.; Mitchell, S. N.; Tricklebank, M.; Williams, S. C. Mapping the central effects of ketamine in the rat using pharmacological MRI Psychopharmacology (Berlin) 2006, 186 (1) 64-81
31. Li, J.; Ishiwari, K.; Conway, M. W.; Francois, J.; Huxter, J.; Lowry, J. P.; Schwarz, A. J.; Tricklebank, M.; Gilmour, G. Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat Neuropsychopharmacology 2014, 39 (7) 1635-1644
32. Gastambide, F.; Mitchell, S. N.; Robbins, T. W.; Tricklebank, M. D.; Gilmour, G. Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat Eur. Neuropsychopharmacol. 2013, 23 (11) 1414-1422
33. Smith, J. W.; Gastambide, F.; Gilmour, G.; Dix, S.; Foss, J.; Lloyd, K.; Malik, N.; Tricklebank, M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory Psychopharmacology 2011, 217 (2) 255-269
34. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 4 th ed.; Academic Press: San Diego, 1998; p 1v.
35. Ernst, A.; Ma, D.; Garcia-Perez, I.; Tsang, T. M.; Kluge, W.; Schwarz, E.; Guest, P. C.; Holmes, E.; Sarnyai, Z.; Bahn, S. Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission J. Proteome Res. 2012, 11 (7) 3704-3714
36. Ernst, A.; Sharma, A. N.; Elased, K. M.; Guest, P. C.; Rahmoune, H.; Bahn, S. Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders Translational Psychiatry 2013, 3
37. Hackstadt, A. J.; Hess, A. M. Filtering for increased power for microarray data analysis BMC Bioinf. 2009, 10, 11
38. Schwender, H., Siggenes: Multiple testing using SAM and Efron's empirical Bayes approaches. R Package, version 1.38.0; 2012.
39. Tusher, V. G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (9) 5116-5121
40. Martins-de-Souza, D.; Menezes de Oliveira, B.; dos Santos Farias, A.; Horiuchi, R. S.; Crepaldi Domingues, C.; de Paula, E.; Marangoni, S.; Gattaz, W. F.; Dias-Neto, E.; Camillo Novello, J. The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis Briefings Funct. Genomic Proteomics 2007, 6 (1) 70-75
41. Picotti, P.; Rinner, O.; Stallmach, R.; Dautel, F.; Farrah, T.; Domon, B.; Wenschuh, H.; Aebersold, R. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes Nat. Methods 2010, 7 (1) 43-U5
42. Lange, V.; Malmstrom, J. A.; Didion, J.; King, N. L.; Johansson, B. P.; Schafer, J.; Rameseder, J.; Wong, C. H.; Deutsch, E. W.; Brusniak, M. Y.; Buhlmann, P.; Bjorck, L.; Domon, B.; Aebersold, R. Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring Mol. Cell. Proteomics 2008, 7 (8) 1489-1500
43. MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen, B.; Kern, R.; Tabb, D. L.; Liebler, D. C.; MacCoss, M. J. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments Bioinformatics 2010, 26 (7) 966-968
44. Farrah, T.; Deutsch, E. W.; Omenn, G. S.; Campbell, D. S.; Sun, Z.; Bletz, J. A.; Mallick, P.; Katz, J. E.; Malmstrom, J.; Ossola, R.; Watts, J. D.; Lin, B. A. Y.; Zhang, H.; Moritz, R. L.; Aebersold, R. A high-confidence human plasma proteome reference set with estimated concentrations in peptide atlas. Mol. Cell. Proteomics 2011, 10, (9).
45. Oberg, A. L.; Vitek, O. Statistical design of quantitative mass spectrometry-based proteomic experiments J. Proteome Res. 2009, 8 (5) 2144-56
46. Chang, C. Y.; Picotti, P.; Huttenhain, R.; Heinzelmann-Schwarz, V.; Jovanovic, M.; Aebersold, R.; Vitek, O. Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol. Cell. Proteomics 2012, 11, (4), 10.1074/mcp.M111.014662.
47. Jin, L. L.; Tong, J. F.; Prakash, A.; Peterman, S. M.; St-Germain, J. R.; Taylor, P.; Trudel, S.; Moran, M. F. Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry J. Proteome Res. 2010, 9 (5) 2752-2761
48. Surinova, S.; Huttenhain, R.; Chang, C. Y.; Espona, L.; Vitek, O.; Aebersold, R. Automated selected reaction monitoring data analysis workflow for large-scale targeted proteomic studies Nat. Protoc. 2013, 8 (8) 1602-1619
49. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing J. R. Stat. Soc., Series B, Methodol. 1995, 57 (1) 289-300
50. Ramsey, A. J. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia Prog. Brain Res. 2009, 179, 51-58
51. Tandon, R.; Keshavan, M. S.; Nasrallah, H. A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology Schizophr. Res. 2008, 102 (1-3) 1-18
52. Treadway, M. T.; Waskom, M. L.; Dillon, D. G.; Holmes, A. J.; Park, M. T.; Chakravarty, M. M.; Dutra, S. J.; Polli, F. E.; Iosifescu, D. V.; Fava, M.; Gabrieli, J. D.; Pizzagalli, D. A. Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. Biol. Psychiatry 2014, 10.1016/j.biopsych.2014.06.018.
53. Campbell, S.; Macqueen, G. The role of the hippocampus in the pathophysiology of major depression J. Psychiatry Neurosci. 2004, 29 (6) 417-426
54. Taniguchi, T.; Kanakura, H.; Takemoto, Y.; Kidani, Y.; Yamamoto, K. Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats Tohoku J. Exp. Med. 2003, 200 (2) 85-92
55. Lankveld, D. P.; Bull, S.; Van Dijk, P.; Fink-Gremmels, J.; Hellebrekers, L. J. Ketamine inhibits LPS-induced tumour necrosis factor-α and interleukin-6 in an equine macrophage cell line Vet. Res. 2005, 36 (2) 257-262
56. Zhu, M. M.; Zhou, Q. H.; Zhu, M. H.; Rong, H. B.; Xu, Y. M.; Qian, Y. N.; Fu, C. Z. Effects of nebulized ketamine on allergen-induced airway hyperresponsiveness and inflammation in actively sensitized Brown-Norway rats J. Inflamm. (London) 2007, 4, 10
57. Gao, M.; Jin, W. J.; Qian, Y. N.; Ji, L. L.; Feng, G. B.; Sun, J. Effect of N -methyl- d -aspartate receptor antagonist on T helper cell differentiation induced by phorbol-myristate-acetate and ionomycin Cytokine 2011, 56 (2) 458-465
58. Di Nicola, M.; Cattaneo, A.; Hepgul, N.; Di Forti, M.; Aitchison, K. J.; Janiri, L.; Murray, R. M.; Dazzan, P.; Pariante, C. M.; Mondelli, V. Serum and gene expression profile of cytokines in first-episode psychosis Brain, Behav., Immun. 2013, 31, 90-95
59. O'Brien, S. M.; Scully, P.; Dinan, T. G. Increased tumor necrosis factor-α concentrations with interleukin-4 concentrations in exacerbations of schizophrenia Psychiatry Res. 2008, 160 (3) 256-62
60. Cohen, R. I.; Chandross, K. J. Fibroblast growth factor-9 modulates the expression of myelin related proteins and multiple fibroblast growth factor receptors in developing oligodendrocytes J. Neurosci. Res. 2000, 61 (3) 273-287
61. Huang, J. Y.; Hong, Y. T.; Chuang, J. I. Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro J. Neurochem. 2009, 109 (5) 1400-1412
62. Morera-Fumero, A. L.; Abreu-Gonzalez, P. Role of melatonin in schizophrenia Int. J. Mol. Sci. 2013, 14 (5) 9037-9050
63. Nakamura, S.; Todo, T.; Motoi, Y.; Haga, S.; Aizawa, T.; Ueki, A.; Ikeda, K. Glial expression of fibroblast growth factor-9 in rat central nervous system Glia 1999, 28 (1) 53-65
64. Palmowski, P.; Rogowska-Wrzesinska, A.; Williamson, J.; Beck, H. C.; Mikkelsen, J. D.; Hansen, H. H.; Jensen, O. N. Acute phencyclidine treatment induces extensive and distinct protein phosphorylation in rat frontal cortex J. Proteome Res. 2014, 13 (3) 1578-1592
65. Smalla, K. H.; Mikhaylova, M.; Sahin, J.; Bernstein, H. G.; Bogerts, B.; Schmitt, A.; van der Schors, R.; Smit, A. B.; Li, K. W.; Gundelfinger, E. D.; Kreutz, M. R. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggests that prohibitin is involved in the synaptic pathology of schizophrenia Mol. Psychiatry 2008, 13 (9) 878-896
66. Wesseling, H.; Chan, M. K.; Tsang, T. M.; Ernst, A.; Peters, F.; Guest, P. C.; Holmes, E.; Bahn, S. A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology Neuropsychopharmacology 2013, 38 (12) 2532-2544
67. Kim, I. H.; Racz, B.; Wang, H.; Burianek, L.; Weinberg, R.; Yasuda, R.; Wetsel, W. C.; Soderling, S. H. Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalities J. Neurosci. 2013, 33 (14) 6081-6092
68. Guest, P. C.; Knowles, M. R.; Molon-Noblot, S.; Salim, K.; Smith, D.; Murray, F.; Laroque, P.; Hunt, S. P.; De Felipe, C.; Rupniak, N. M.; McAllister, G. Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling Brain Res. 2004, 1002 (1-2) 1-10
69. Reines, A.; Cereseto, M.; Ferrero, A.; Sifonios, L.; Podesta, M. F.; Wikinski, S. Maintenance treatment with fluoxetine is necessary to sustain normal levels of synaptic markers in an experimental model of depression: correlation with behavioral response Neuropsychopharmacology 2008, 33 (8) 1896-1908
70. Gerber, D. J.; Hall, D.; Miyakawa, T.; Demars, S.; Gogos, J. A.; Karayiorgou, M.; Tonegawa, S. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (15) 8993-8998
71. Eastwood, S. L.; Burnet, P. W.; Harrison, P. J. Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia Biol. Psychiatry 2005, 57 (7) 702-710
72. Miyakawa, T.; Leiter, L. M.; Gerber, D. J.; Gainetdinov, R. R.; Sotnikova, T. D.; Zeng, H.; Caron, M. G.; Tonegawa, S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (15) 8987-3992
73. Yu, J. J.; Zhang, Y.; Wang, Y.; Wen, Z. Y.; Liu, X. H.; Qin, J.; Yang, J. L. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway Psychopharmacology 2013, 225 (2) 361-372
74. Crozatier, C.; Farley, S.; Mansuy, I. M.; Dumas, S.; Giros, B.; Tzavara, E. T. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants Neuroscience 2007, 144 (4) 1470-1476
75. Bahi, A.; Mineur, Y. S.; Picciotto, M. R. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice Biol. Psychiatry 2009, 66 (12) 1139-1146
76. Li, L. A.; Xu, B. Z.; Zhu, Y.; Chen, L.; Sokabe, M.; Chen, L. DHEA prevents A beta(25-35)-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling Neuropharmacology 2010, 59 (4-5) 323-333
77. Dwyer, J. M.; Duman, R. S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants Biol. Psychiatry 2013, 73 (12) 1189-1198
78. Jernigan, C. S.; Goswami, D. B.; Austin, M. C.; Iyo, A. H.; Chandran, A.; Stockmeier, C. A.; Karolewicz, B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35 (7) 1774-1779
79. Hoeffer, C. A.; Klann, E. mTOR signaling: At the crossroads of plasticity, memory and disease Trends Neurosci. 2010, 33 (2) 67-75
80. Bear, M. F.; Huber, K. M.; Warren, S. T. The mGluR theory of fragile X mental retardation Trends Neurosci. 2004, 27 (7) 370-377
81. Nakanishi, S.; Nakajima, Y.; Masu, M.; Ueda, Y.; Nakahara, K.; Watanabe, D.; Yamaguchi, S.; Kawabata, S.; Okada, M. Glutamate receptors: brain function and signal transduction Brain Res. Brain Res. Rev. 1998, 26 (2-3) 230-235
82. Palucha, A.; Pilc, A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs Pharmacol. Ther. 2007, 115 (1) 116-147
83. Silver, H.; Feldman, P.; Bilker, W.; Gur, R. C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia Am. J. Psychiatry 2003, 160 (10) 1809-1816
84. Arnsten, A. F. Ameliorating prefrontal cortical dysfunction in mental illness: inhibition of phosphotidyl inositol-protein kinase C signaling Psychopharmacology (Berlin) 2009, 202 (1-3) 445-455
85. Chen, R.; Daining, C. P.; Sun, H.; Fraser, R.; Stokes, S. L.; Leitges, M.; Gnegy, M. E. Protein kinase C is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter J. Neurochem. 2013, 125 (5) 663-672
86. Silver, H.; Susser, E.; Danovich, L.; Bilker, W.; Youdim, M.; Goldin, V.; Weinreb, O. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients Int. J. Neuropsychopharmacol. 2011, 14 (5) 573-584
87. Liu, H.; Abecasis, G. R.; Heath, S. C.; Knowles, A.; Demars, S.; Chen, Y. J.; Roos, J. L.; Rapoport, J. L.; Gogos, J. A.; Karayiorgou, M. Genetic variation in the 22q11 locus and susceptibility to schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (26) 16859-16864
88. Shifman, S.; Bronstein, M.; Sternfeld, M.; Pisante-Shalom, A.; Lev-Lehman, E.; Weizman, A.; Reznik, I.; Spivak, B.; Grisaru, N.; Karp, L.; Schiffer, R.; Kotler, M.; Strous, R. D.; Swartz-Vanetik, M.; Knobler, H. Y.; Shinar, E.; Beckmann, J. S.; Yakir, B.; Risch, N.; Zak, N. B.; Darvasi, A. A highly significant association between a COMT haplotype and schizophrenia Am. J. Hum. Genet. 2002, 71 (6) 1296-1302
89. Egan, M. F.; Goldberg, T. E.; Kolachana, B. S.; Callicott, J. H.; Mazzanti, C. M.; Straub, R. E.; Goldman, D.; Weinberger, D. R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (12) 6917-6922
90. Fukui, N.; Suzuki, Y.; Sugai, T.; Watanabe, J.; Ono, S.; Tsuneyama, N.; Someya, T. Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression Psychiatry Res. 2014, 218 (3) 353-355
91. Curley, A. A.; Eggan, S. M.; Lazarus, M. S.; Huang, Z. J.; Volk, D. W.; Lewis, D. A. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia Neurobiol. Disease 2013, 50, 179-186
92. Sarnyai, Z.; Alsaif, M.; Bohn, S.; Ernst, A.; Guest, P. C.; Hradetzky, E.; Kluge, W.; Stelzhammer, V.; Wesseling, H. Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders Int. Rev. Neurobiol. 2011, 101, 203-238
93. Schobel, S. A.; Chaudhury, N. H.; Khan, U. A.; Paniagua, B.; Styner, M. A.; Asllani, I.; Inbar, B. P.; Corcoran, C. M.; Lieberman, J. A.; Moore, H.; Small, S. A. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver Neuron 2013, 78 (1) 81-93
94. Stan, A. D.; Ghose, S.; Zhao, C.; Hulsey, K.; Mihalakos, P.; Yanagi, M.; Morris, S. U.; Bartko, J. J.; Choi, C.; Tamminga, C. A., Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol. Psychiatry 2014, 10.1038/mp.2014.54.
95. Paul, I. A.; Skolnick, P. Glutamate and depression: clinical and preclinical studies Ann. N.Y. Acad. Sci. 2003, 1003, 250-272
96. Schubert, K. O.; Focking, M.; Prehn, J. H. M.; Cotter, D. R. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol. Psychiatry 2012, 17 (7) 669-681
97. Gottschalk, M. G.; Wesseling, H.; Guest, P. C.; Bahn, S. Int. J. Neuropsychopharmacol. 2014, 10.1093/ijnp/pyu019
98. Zhu, G.; Okada, M.; Uchiyama, D.; Ohkubo, T.; Yoshida, S.; Kaneko, S. Hyperactivity of endoplasmic reticulum associated exocytosis mechanism contributes to acute phencyclidine intoxication J. Pharmacol. Sci. 2004, 95 (2) 214-227
99. Pickering, C.; Ericson, M.; Soderpalm, B. Chronic phencyclidine increases synapsin-1 and synaptic adaptation proteins in the medial prefrontal cortex ISRN Psychiatry 2013, 620361